Key facts
- This page summarizes Glen Burkhardt's Form 4 filing for PhaseBio Pharmaceuticals Inc.
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 24 May 2022, 17:14.
Glen Burkhardt - 20 May 2022 Form 4 Insider Report for PhaseBio Pharmaceuticals Inc
- Reporting relationship
- SVP of Human Resources
- Issuer ticker
- N/A
- Reported as of
- 20 May 2022
- Net transaction value
- -$1,223
- SEC form
- 4
- Accepted by SEC
- 24 May 2022, 17:14:08 UTC
- Prior SEC filing
- 28 Feb 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ John P. Sharp, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Glen Burkhardt filed Form 4 for PhaseBio Pharmaceuticals Inc on 24 May 2022.
Change
- Previous filing in this sequence was filed on 28 Feb 2022.
- Current net transaction value: -$1,223.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PHASQ
transaction
Common Stock
Award
- Transaction value
- $7,663
- Shares
- +11,248
- Change %
- Price
- $0.6813*
- Shares after
- 11,248
- Date
- 20 May 2022
- Ownership
- Direct
- Footnotes
- F1, F2
PHASQ
transaction
Common Stock
Sale
- Transaction value
- $8,886
- Shares
- -11,248
- Change %
- -100%
- Price
- $0.7900*
- Shares after
- 0
- Date
- 23 May 2022
- Ownership
- Direct
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Shares were acquired under the Issuer's Employee Stock Purchase Plan ("ESPP") in a transaction that is exempt under both Rule 16b-3(c) and Rule 16b-3(d).
Footnote F2
In accordance with the ESPP provisions, these shares were purchased based on 85% of the closing price of the Issuer's common stock on May 20, 2022.
Footnote F3
The shares reported were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.